Tasly Pharmaceutical Group Co Ltd
SSE:600535
Tasly Pharmaceutical Group Co Ltd's latest stock split occurred on Jun 5, 2018
The company executed a 7-for-5 stock split, meaning that for every 5 shares held, investors received 7 new shares.
Before the split, Tasly Pharmaceutical Group Co Ltd traded at 39.6101 per share. Afterward, the share price was about 25.7524.
The adjusted shares began trading on Jun 5, 2018. This was Tasly Pharmaceutical Group Co Ltd's 4th stock split, following the previous one in May 22, 2013.
WTO
Tasly Pharmaceutical Group Co Ltd
Glance View
In the heart of China's bustling pharmaceutical landscape lies Tasly Pharmaceutical Group Co Ltd, a company intricately blending traditional herbal wisdom with cutting-edge scientific innovation. Founded in 1994, this enterprise has carved a niche in the competitive world of healthcare by focusing on Traditional Chinese Medicine (TCM) while also expanding into chemical medicine and biological drugs. Tasly's ecosystem thrives on the research, development, manufacturing, and marketing of its diverse product portfolio, which includes patent medicines, herbal injections, and health supplements. The crown jewel in its product lineup is the Compound Danshen Dripping Pill, a herbal medicine aimed at cardiovascular ailments, a testament to the company's commitment to merging ancient remedies with modern health solutions. By establishing an extensive distribution network both domestically and internationally, Tasly ensures its unique offerings reach a wide audience, catering not only to China's growing appetite for health products but also tapping into global markets hungry for alternative medicine solutions. Tasly’s financial engine leverages its broad spectrum of offerings, driven by both consumer demand for TCM and the pharmaceutical industry's appetite for innovation. The company invests significantly in research and development, with a particular emphasis on internationalizing TCM and obtaining global recognition for its products through clinical trials and partnerships. Such strategic actions bolster its competitive edge, positioning Tasly as a leader in an industry where tradition and science converge. Revenue streams are further diversified by the company's health management services and a growing footprint in biotechnology, showcasing its adaptability and forward-thinking approach. This intricate ballet of innovation and tradition enables Tasly Pharmaceutical Group to not just survive but thrive in an industry characterized by rapid advancements and shifting consumer paradigms.
You don't have any saved screeners yet